Timing of Tracheostomy in COVID-19 - Impact on Mortality

How timing of tracheostomy in COVID-19 patients changed and its impact on mortality in patients with severe COVID-19 ARDS

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tracheostomy

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Frankfurt

Niederrad, Hesse, 60590, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Severe COVID-19 infection requiring endotracheal intubation and prolonged invasive ventilation as part of the treatment of severe to moderate acute respiratory distress syndrome.

Exclusion criteria

COVID-19 disease, without the need for endotracheal ventilation.
COVID-19 disease with need for endotracheal intubation with anticipated short-term invasive ventilation.

Treatment and study plan

Primary outcomes

Mortality

Time frame: During intensive care treatment (Usually within 8 weeks)

Deaths in the course of treatment

Sponsors and collaborators

Lead sponsor

Goethe University

Other

Registry information

Official study title

How Timing of Tracheostomy in COVID-19 Patients Changed and Its Impact on Mortality

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Jan 4, 2022
Registry last updated: Jan 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed